抗加齢医学研究部
1.

Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y,Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S,Nagai R & Nabeshima Y. Mutation of the mouse klotho gene leads to a syndrome
resembling ageing. Nature 390, 45-51 (1997).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citati
on&list_uids=9363890

2.

Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP,Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR,Rosenblatt KP & Kuro-o M. Suppression of Aging in Mice by the Hormone Klotho.
Science 309, 1829-1833 (2005).
http://www.sciencemag.org/cgi/content/abstract/1112766v1

3.

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG,
Schiavi S, Hu MC, Moe OW & Kuro-o M. Regulation of fibroblast growth factor-23
signaling by klotho. J Biol Chem 281, 6120-6123 (2006).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citati
on&list_uids=16436388

4.

Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert
TA, Zhang F, Linhardt RJ, Yu X, White KE, Inagaki T, Kliewer SA, Yamamoto M, Kurosu
H, Ogawa Y, Kuro-o M, Lanske B, Razzaque MS & Mohammadi M. Molecular insights
into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19
subfamily members. Mol Cell Biol 27, 3417-3428 (2007).
https://www.ncbi.nlm.nih.gov/pubmed/17339340

5.

Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, Eliseenkova AV,Mohammadi M & Kuro-o M. βKlotho is required for metabolic activity of fibroblast growth
factor 21. Proc Natl Acad Sci U S A 104, 7432-7437 (2007).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citati
on&list_uids=17452648

6.

Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M,
Rosenblatt KP, Kliewer SA & Kuro-o M. Tissue-specific expression of betaKlotho andfibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19and FGF21. J Biol Chem 282, 26687-26695 (2007).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citati
on&list_uids=17623664
7.

Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV,Razzaque MS, Moe OW, Kuro-o M & Mohammadi M. Isolated C-terminal tail of FGF23
alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.
Proc Natl Acad Sci U S A 107, 407-412 (2010).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citati
on&list_uids=19966287

8.

Hu MC, Shi M, Zhang J, Quinones H, Kuro-o M & Moe OW. Klotho deficiency is an earlybiomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney
Int 78, 1240-1251 (2010).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citati
on&list_uids=20861825

9.

Xie J, Cha SK, An SW, Kuro-o M, Birnbaumer L & Huang CL. Cardioprotection by Klotho
through downregulation of TRPC6 channels in the mouse heart. Nat Commun 3, 1238
(2012).
https://www.ncbi.nlm.nih.gov/pubmed/23212367

10. Hu MC, Shiizaki K, Kuro-o M & Moe OW. Fibroblast growth factor 23 and klotho:
physiology and pathophysiology of an endocrine network of mineral metabolism. Annu
Rev Physiol 75, 503-533 (2013).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citati
on&list_uids=23398153
11. Hu MC, Shi M, Cho HJ, Adams-Huet B, Paek J, Hill K, Shelton J, Amaral AP, Faul C,Taniguchi M, Wolf M, Brand M, Takahashi M, Kuro-o M, Hill JA & Moe OW. Klotho andphosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol
26, 1290-1302 (2015).
http://www.ncbi.nlm.nih.gov/pubmed/25326585
12. Hu MC, Shi M, Zhang J, Addo T, Cho HJ, Barker SL, Ravikumar P, Gillings N, Bian A,Sidhu SS, Kuro-o M & Moe OW. Renal Production, Uptake, and Handling of CirculatingalphaKlotho. J Am Soc Nephrol 27, 79-90 (2016).
https://www.ncbi.nlm.nih.gov/pubmed/25977312
13. Miura Y, Iwazu Y, Shiizaki K, Akimoto T, Kotani K, Kurabayashi M, Kurosu H & Kuro-oM. Identification and quantification of plasma calciprotein particles with distinct physicalproperties in patients with chronic kidney disease. Sci Rep 8, 1256 (2018).
https://www.ncbi.nlm.nih.gov/pubmed/29352150
14. Stenvinkel P, Painer J, Kuro-o M, Lanaspa M, Arnold,W, Ruf T, Shiels PG & Johnson
RJ. Novel treatment strategies for chronic kidney disease: insights from the animalkingdom. Nat Rev Nephrol 14, 265-284 (2018).
https://www.ncbi.nlm.nih.gov/pubmed/29332935
15. Kuro-o M. Ageing-related receptors resolved. Nature 553, 409-410, (2018).
https://www.ncbi.nlm.nih.gov/pubmed/?term=Kuro-o+nature+ageing-related
16. Kuro-o M. The Klotho proteins in health and disease. Nat Rev Nephrol 15, 27-44 (2019).
https://www.ncbi.nlm.nih.gov/pubmed/30455427